clinical trial · NCT07441460
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.·phase3·recruiting·n = 1,800
Resectable HER2-positive Breast CancerKN026HB1801TrastuzumabPertuzumabDocetaxelEpirubicinDoxorubicinCyclophosphamide
brief summary
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.
started
Mar 6, 2026
primary completion
Aug 7, 2034
completion
Aug 7, 2035
last updated
Apr 8, 2026
official title
A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of KN026 Combined With HB1801 and Chemotherapy Versus Trastuzumab Combined With Pertuzumab and Chemotherapy as Adjuvant Therapy in Resectable HER2-positive Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol